spacer
home > ict > autumn 2016 > lessons learned
PUBLICATIONS
International Clinical Trials

Lessons Learned

When validating the one million data points that compose a typical Phase 3 trial, focusing on irrelevant mistakes could easily result in wasted resources. The industry’s initial response – in the form of risk-based monitoring (RBM) – detects errors and risks more efficiently, but can still expend resources on errors not pertinent to a study’s validity and, therefore, miss opportunities to define and solve critical quality issues.

What if we were to look to other industries’ strategies for risk mitigation, in order to evolve RBM into a more useful approach for protecting clinical data? One of these methodologies – namely human factor analysis (HFA) – is employed by NASA, Ford, the US Environmental Protection Agency, major airlines and several countries’ militaries to identify and mitigate human error in large, variously trained workforces. Closer to the pharmaceutical sector, human factors are the core to the foundation training by the WHO in its education on patient safety (1). HFA uses uniquely structured datasets to show underlying behaviours that are otherwise difficult for humans to sense or reconstruct but are, ultimately, the root cause of an incident.

Consider a site that has multiple issues with informed consent. A traditional monitoring approach would log a problem, potentially announce the site as high risk and deploy general retraining on informed consent. Instead, using HFA allows one to look for trends in the data and classify what they revealed in predetermined categories; for instance, consent errors became more frequent after that site had enrolled 100 or more patients. To mitigate risk, the project team could perhaps limit the site to no more than 75 patients and provide additional investigator support focusing on resource allocation.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Clara Heering is Senior Vice President of Clinical Risk and Data Management at ICON, and has over 20 years’ experience in clinical research, which spans both CRO and pharma industries. Clara's previous experience includes 16 years at Pfizer and two years as Research Fellow at Harvard Medical School, US. She holds a degree in Risk Management and in Medical Biology.
spacer
Clara Heering
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Over 1500 cargo flights during 100 days

June 2020 Saudia Cargo has operated more than 1500 flights since the COVID-19 restrictions came into effect in March. 500 of these flights have been operated using passenger aircraft deployed for international air cargo, according to an announcement by the company. The move reflects the efforts the company has exerted to fight COVID-19.
More info >>

White Papers

8 Ways To Reduce Tablet Manufacturing Costs

Natoli Engineering Company, Inc.

It’s no surprise that in today’s economy, companies are facing budget cuts across the board. In an effort to address these challenges, this list of 8 Ways to Reduce Tablet Manufacturing Costs was compiled.
More info >>

 
Industry Events

Formulation and Drug Delivery Series UK

8-9 July 2020, Oxford Global

This event brings together leading formulation, drug delivery and biologics manufacturing experts from around the world across two days. The panel of prominent industry leaders and world-leading scientists will share the latest case studies, innovative developments for novel therapeutic products and strategies for drug development.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement